737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Danska-Bidzinska A, Makker V, Salutari V, Ayhan A, Romero I, Levy T, McCormack M, Baurain J, Mach P, Cadoo K, Mackay H, Friedlander M, Santin A, Slomovitz B, Miller D, McKenzie J, Yao L, Khemka V, Nogueira-Rodrigues A, Marth C. 737P Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study. Annals Of Oncology 2024, 35: s561. DOI: 10.1016/j.annonc.2024.08.799.Peer-Reviewed Original ResearchTumor response